Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT trial
2024-518611-18-00Phase 2Authorised
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced cardiotoxicity (CIC) and breast cancer comparing Dapagliflozin arm with Placebo arm (2 arms). Primary endpoint: Rate of asymptomatic and symptomatic cancer therapy-related cardiac dysfunction (CTRCD). Planned start Dec 2024; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)breast cancer
Beyond the preview
Go deeper on 2024-518611-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518611-18-00.